Company profile
BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACORAMIDIS HYDROCHLORIDE | approved | — | 0 | — |
| ACORAMIDIS | phase3 | — | 4 | active |
| INFIGRATINIB | phase2 | — | 8 | completed, terminated |
| BBP-398 | phase1_2 | — | 3 | terminated |
| BBO-8520 | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (33)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04836494 | phase1 | terminated | 2021-03-25 | 2023-11-20 | CoA Therapeutics, Inc., a BridgeBio company | A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia |
| NCT02150967 | phase2 | terminated | 2014-07-23 | 2021-03-01 | QED Therapeutics, a BridgeBio company | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma |
| NCT04769479 | phase1 | completed | 2021-03-28 | 2021-08-04 | Eidos Therapeutics, a BridgeBio company | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects |
| NCT04876924 | phase1 | completed | 2021-04-29 | 2022-02-27 | Cantero Therapeutics, a BridgeBio company | A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers |
| NCT06164951 | phase3 | completed | 2023-11-10 | 2025-12-18 | QED Therapeutics, a BridgeBio company | A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 216540 | NDA | BRIDGEBIO PHARMA INC | ||||
Loading… | ||||||